PDCD1 and cancer: Another study explored the interest of radiomics as a non-invasive biomarker for responses to cancer immunotherapy on 1055 primary and metastatic lesions from 203 contrast-enhanced CTs from patients with advanced melanoma and NSCLC, undergoing anti-PD1 therapy [48].